Integrating Digital Phenotypes and AI-Driven Cognitive-Behavioral Therapy: Advancing Precision Medicine in Depression Through Digital Medicine
National Science and Technology Council, Taiwan
100 participants
Jun 1, 2025
INTERVENTIONAL
Conditions
Summary
This project aims to integrate digital phenotyping and AI-driven iCBT into a comprehensive platform for MDD diagnosis and treatment in Taiwan. The study will explore dynamic, real-time behavioral and physiological markers to refine diagnostic classifications and optimize personalized therapeutic strategies.
Eligibility
Inclusion Criteria5
- (1) Aged 18-75 years
- Diagnosis of major depressive disorder disorder (Based on Diagnostic Statistical Manual 5)
- item Hamilton Depression Scale (HAMD21)\>17
- No changes in current psychiatric treatment for depression (e.g., no treatment, antidepressant medication, psychotherapy, or non-invasive brain stimulation) within the past four weeks, and
- Full competency to understand the study details and provide written informed consent
Exclusion Criteria3
- Scores of 5 ( Markedly ill), 6,(Severely ill), and 7 (Among the most extremely ill) according to the Clinical Global Impression Scale-Severity (CGI-S)
- Psychotic disorders, bipolar affective disorder, a substance use disorders in the past 6 months, active suicidal or homicidal ideation (per assessment or HAMD\>3)
- Unstable or active medical illness.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
GPT-powered iCBT the participants will receive 8 sessions (30 minutes per session)
Sham (relaxation/supportive interaction) treatment at Day 2, 5, 9, 12, 16, 19, 23, 27.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07500714